ZPRÁVA O PRŮBĚHU KLINICKÉHO HODNOCENÍ HALF (16.6.2021 – 15.6.2022)
| Title in English | REPORT ON THE PROGRESS OF THE HALF CLINICAL TRIAL (16/06/2021 – 15/06/2022) |
|---|---|
| Authors | |
| Year of publication | 2022 |
| MU Faculty or unit | |
| Web | HALF |
| Description | Phase II prospective clinical study evaluating the efficacy and safety of tyrosine kinase inhibitors after previous two-stage dose reduction in patients with chronic myeloid leukemia in deep molecular remission. |
| Related projects: |